

RESEARCH

Open Access



# Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda

Giovanni Guaraldi<sup>1</sup>, Paolo Bonfanti<sup>2,3</sup>, Antonio Di Biagio<sup>4</sup>, Andrea Gori<sup>5,6\*</sup>, Jovana Milić<sup>1</sup>, Paola Saltini<sup>5,6</sup>, Francesco V. Segala<sup>7</sup>, Nicola Squillace<sup>2</sup>, Lucia Taramasso<sup>4</sup> and Antonella Cingolani<sup>7</sup>

## Abstract

**Background** Combined antiretroviral therapy (cART) dramatically improved survival in people living with HIV (PLWH) but is associated with weight gain (WG), raising concern for a possible obesity epidemic in PLWH. This scoping review aims to identify the gaps in the existing evidence on WG in PLWH and generate a future research agenda.

**Methods** This review was conducted according to the methodology for scoping studies and reported according to the PRISMA Extension for Scoping Review checklist. Articles published in English in the last 10 years indexed in Pubmed, WHO Global Index Medicus, or Embase were searched using specific queries focused on WG in PLWH.

**Results** Following the selection process, 175 included articles were reviewed to search for the available evidence on four specific topics: (I) definition of WG in PLWH, (II) pathogenesis of WG in PLWH, (III) impact of ART on WG, (IV) correlation of WG with clinical outcomes. A summary of the data enabled us to identify gaps and clearly define the following research agenda: (I) develop a data-driven definition of WG in PLWH and define noninvasive assessment methods for body weight and fat composition; (II) further investigate the interaction between HIV/cART and immunity, metabolism, and adipose tissue; (III) establish the specific role of individual drugs on WG; (IV) clarify the independent role of WG, cART, HIV, and metabolic factors on clinical events.

**Conclusions** The proposed research agenda may help define future research and fill the knowledge gaps that have emerged from this review.

**Keywords** Antiretroviral therapy, HIV, Research agenda, Weight gain

\*Correspondence:

Andrea Gori  
andrea.gori@unimi.it

<sup>1</sup>HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy

<sup>2</sup>Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

<sup>3</sup>University of Milano-Bicocca, Milan, Italy

<sup>4</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino, University of Genova, Genova, Italy

<sup>5</sup>Infectious Diseases Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>6</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

<sup>7</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli-Università Cattolica Del Sacro Cuore, Rome, Italy



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Since the beginning of the HIV epidemic, it was clear that both HIV and antiretrovirals (ARVs) contributed to body composition changes in people living with HIV (PLWH). The “slim disease” was the first name given to AIDS to identify the main clinical presentation of the wasting syndrome affecting PLWH [1]. The use of combined antiretroviral therapy (cART) has dramatically improved the survival of PLWH. However, earlier cART medications were implicated in causing lipodystrophy, characterized by peripheral subcutaneous lipoatrophy and central/abdominal lipohypertrophy, and increased the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).

Current cART, in particular integrase strand transfer inhibitors (INSTIs), are not related to peripheral lipoatrophy but are associated with weight gain (WG), which raises concern for a possible obesity epidemic in PLWH. Recently, tenofovir alafenamide (TAF), independent of INSTI use, has also been linked to WG [2–7].

The objective of this scoping review was to identify gaps in the existing evidence on WG in PLWH and to generate a research agenda on body composition changes in PLWH. Specifically, the following research questions (RQ) were addressed: (I) what is the available evidence/consensus on the definition of WG in PLWH; (II) what is the available evidence on pathogenesis; (III) what is the available evidence on the impact of ART on WG; (IV) what is the available evidence on the correlation between WG and clinical outcomes.

## Methods

This scoping review was conducted according to the methodological framework developed by Arksey and O'Malley [8] and refined by Levac and colleagues [9]. Reporting was performed according to the PRISMA Extension for Scoping Review checklist (Supplemental Digital Content 1), with no registration on any specific database for scoping reviews [10]. Articles published in English in the 10-year-period 2011–2021 indexed in Pubmed, WHO Global Index Medicus, or Embase were searched using specific queries focused on WG in PLWH. The search was performed on 31st October 2021. A search update was performed during October 2022, with the inclusion of 9 new records. The full search strategy and the scoping review protocol are detailed in Supplemental Digital Content 2.

## Results

### Selection of studies

Initial database extraction yielded 835 results (468 after duplicate removal). Of these, 283 were excluded, and 185 full-text articles were assessed for eligibility, which led to the inclusion of 157 articles for qualitative synthesis.

During manuscript writing, additional 18 recent relevant articles were retrieved by authors (Fig. 1).

### Study characteristics

Among the 175 included articles, there were 139 original research articles, 23 reviews and 6 systematic reviews, 6 congress abstracts/presentations and 1 report from the European Medicines Agency (Supplemental Digital Content 3). Unsurprisingly, most covered aspects related to the role of cART in WG, while other areas were less well represented (Table 1).

### RQ1. What is the available evidence/consensus on the definition of WG in PLWH?

Current literature regarding WG in PLWH suggests a definition criterion evaluating either a continuous measure of weight or an arbitrary cut-off such as a 5% weight increase or a body mass index (BMI) increase of 7%. The former cut-off of 5% is derived from recommended lifestyle interventions for weight loss as treatment of cardiometabolic conditions in the general population [11]. The latter has been used to describe the toxicities of antipsychotic drugs [12]. A recently published paper from Modena HIV Metabolic Clinic (MHMC) analyzed 54,826 weight assessments to identify WG cut off associated with the incidence of insulin resistance. A weight increase by 1% reduced the total protective effect of INSTI by 21.1% over 1 year of follow-up, which identifies a 5% weight increase as a clinically meaningful weight gain definition [13].

### WG definition

We searched the WG definition employed in published articles on PLWH. Of the 157 included articles, we assessed 119 original research articles with relevant data on the definition of WG for this subtopic. WG relied on the assessment of weight in 52 (43.7%) studies, of BMI in 28 (23.5%) studies, and both in 37 (31.1%) studies, while other definitions such as fat gain were used in 2 (1.7%) studies only. In most papers, WG was defined as the absolute or percentage change in weight or BMI from baseline (76 studies; 63.9%), while 17 (14.3%) studies used an arbitrary pre-defined criterion, and 26 (21.8%) studies used both criteria. BMI categories of overweight and obesity were considered in 21 (17.6%) studies, whereas 17 (14.3%) studies considered a WG cut-off of 5–10%, and 11 (9.2%) studies used different definitions. The main issues related to the definition of WG in these studies are discussed below.

Most studies do not evaluate WG using a standardized follow-up period but rather measure the linear increase in weight or BMI over time. However, observational data shows that in PLWH, weight increases annually due to aging, but a more rapid increase may be observed in the




Fig. 1 PRISMA flow diagram

Table 1 Topics of interest and distribution among included articles

			No. studies (%)
RQ1	Definition of WG in PLWH	WG definition used/metrics considered (ORA only)	119 (76%)
		Body composition and distribution of fat	35 (22%)
RQ2	Pathogenesis of WG in PLWH		108 (69%)
RQ3	Impact of ART on WG		142 (90%)
RQ4	Correlation of WG with clinical outcomes among PLWH		89 (57%)

ART: antiretroviral therapy; ORA: original research articles; PLWH: people living with HIV; RQ: research question; WG: weight gain

first 6–12 months of therapy, particularly in people starting or switching to INSTIs. After this period, the WG trend may or may not return to parallel that observed in the general population [6]. The choice to use the absolute or percentage increase in weight or BMI is arbitrary, and the result depends mainly on the absolute value of the weight or BMI at the time of initiation or change of cART. None of the definitions mentioned above appear to be data-driven or validated in PLWH, and debate continues

on the best clinical outcome measure to define clinically meaningful WG. Furthermore, WG should be considered in the context of relevant anthropometric changes that differ in ethnicity, sex, and age. For example, traditional BMI cut-offs underestimate cardiometabolic risk in the Asian population [14]. Finally, it remains unclear whether WG is synonymous with fat gain.

**Body composition and distribution of fat**

Although BMI may be a convenient and simple index to monitor the increasing prevalence of obesity at the population level, studies have shown that obesity defined by BMI is remarkably heterogeneous [15], and people with similar BMI can have substantially different comorbidities [16]. Data from several epidemiological studies over the past 30 years have shown that ectopic fat, namely visceral adipose tissue (VAT), epicardial adipose tissue, and liver fat, are independent markers of morbidity and mortality, and that the accumulation of abdominal subcutaneous adipose tissue (SAT) is a weak indicator of CV risk [17, 18]. Dual-energy X-ray absorptiometry (DEXA), computed tomography (CT), and magnetic resonance imaging (MRI) should be used to assess fat and lean mass in both observational and clinical trials in order to understand the WG phenomenon better. Among the 119 original research articles analyzed for RQ1, we identified

9 (7.6%) studies that assessed body composition with DEXA and 8 (6.7%) studies that assessed VAT components with CT or MRI. A milestone in this research area was the FRAM2 study [19]. In this study, the association between regional and total musculoskeletal tissue and adipose tissue (AT) was determined by MRI after 5 years of follow-up. After multivariate adjustments, lower arm skeletal muscle, lower leg skeletal muscle, and upper VAT were independently associated with increased mortality. The ADVANCE study included an analysis of VAT by DEXA at 96 weeks of follow-up [20]. This study compared the efficacy and safety of two first-line cART regimens (DTG+emtricitabine and either tenofovir disoproxil fumarate [TDF] or tenofovir alafenamide [TAF]) with a third regimen (efavirenz+emtricitabine+TDF). In all treatment groups, the increase in fat mass was higher than lean mass and was distributed between trunk and limbs, and a similar increase in VAT and SAT was observed. The increase in VAT between baseline and week 96 was higher in women than men, although the difference was not statistically significant, and was higher in the TAF group regarding changes in mass and volume ( $p < 0.001$  for all comparisons) [21]. The ACTG A5260s randomized clinical trial including 234 PLWH showed that greater trunk, limb, VAT, and SAT, assessed by CT, were associated with insulin resistance and increased systemic inflammation, implying a strong relationship between fat deposits and hard metabolic outcomes over 96 weeks of follow-up [22]. Most studies evaluating the relationships between AT and health outcomes focus on the amount and distribution of AT [19, 23]. However, the quality of AT can also be indirectly assessed by measuring its density (in Hounsfield units, HU) on CT [24, 25]. As fat increases, the AT deposits can expand by hyperplasia (generation of new adipocytes of similar size), in which the density remains stable, or hypertrophy (existing adipocytes become lipid-engorged), in which the density decreases [26, 27]. Conversely, with wasting, the adipocytes become smaller and contain fewer lipids, which is reflected by an increase in density [28, 29]. Inflammation and fibrosis of the AT can also cause an increase in its density [24], which may be a marker of AT dysfunction [29, 30] and potentially increased cardiometabolic risk [26, 28]. On the other hand, lower VAT and SAT density (which reflects fat engorgement of adipocytes, likely without progression to significant fibrosis) was associated with increased cardiometabolic risk, higher levels of circulating leptin, and lower levels of adiponectin [24, 31]. Another study that included 418 PLWH who switched to INSTIs showed that a higher increase in BMI over the 4-year follow-up was associated with a lower VAT density, suggesting improved fat quality [32].

## **RQ2. What is the available evidence on the pathogenesis of WG in PLWH?**

The complex, interrelated mechanisms in WG associated with cART in PLWH are not yet fully understood.

### **Role of HIV and/or inflammation**

HIV-associated wasting accompanying advanced CD4 cell depletion is characterized by an increase in basal metabolism, which can increase further during opportunistic infections. Anorexia, secondary to the effect of elevated inflammatory markers on the hypothalamus, also occurs at this stage of the disease [33]. ART initiation reverses this metabolic state and reduces inflammation, reflecting a reduced metabolic demand in the state of controlled infection, possibly leading to WG. Several studies showed that PLWH with lower CD4 counts and higher viral loads (VL) at ART initiation gain more weight after treatment initiation [34, 35]. The Swiss HIV Cohort study showed that a lower CD4 nadir is a significant risk factor for developing general and visceral obesity; in particular, a 2-fold increased risk of general obesity was observed in patients with CD4 nadir  $< 100$  cell/ $\mu$ L [36]. In the Italian SCOLTA cohort, patients in CDC stage C treated with different ARV had a higher BMI increase than patients in stage A and B [37]. The results of these studies support the hypothesis that WG may be interpreted, at least in part, as a “return to health” phenomenon, characterized by reduced or suppressed viral replication, a reduced metabolic demand by the virus, and a better control of inflammation [38]. In a study conducted among people with acute and early HIV infection, VL and CD4 nadir were not identified as risk factors for WG after ART initiation. A possible explanation for this unexpected finding is that the duration of infection could play a role in WG. Moreover, HIV-RNA and CD4 count in acute and early HIV infection have a unique dynamic that weakens their associations with weight change [39]. HIV-associated immune activation persists despite suppressive ART. Innate and adaptive immunity cells are also located in the stromal vascular fraction of AT, where they modulate adipocyte energy storage and function, and inflammation [35]. Macrophages accumulate in AT with progressive WG. Adipocytes and macrophages produce the monocyte chemoattractant protein 1 (MCP-1), which drives the increase in TNF $\alpha$ , IL-6, IL-12, and IL-23. A study of gluteal fold AT showed similar macrophage density between PLWH and HIV-negative controls but higher IL-6, IL-8, IL-12p40, and monocyte inflammatory protein 1 $\alpha$  (MIP1 $\alpha$ ) levels in the HIV-positive population [40]. In a French cohort of patients with normal weight at ART initiation, who achieved virologic suppression, most inflammatory biomarkers, namely CXCL8, sTNFR1, sTNFR2, and sCD163, were significantly higher in patients who became overweight or obese [41]. These

inflammatory biomarkers tend to decrease with ART in the setting of a controlled infection. Accordingly, also in two large randomized ACTG trials A5202 and A5257, it was observed that among non-obese persons, higher pre-treatment immune activation markers significantly associated with WG in course of ART, while WG attenuated the decline in several immune activation markers following ART initiation [42]. Furthermore, it is known that lipopolysaccharide (LPS), which is increased in PLWH because of the breach of the gut barrier, facilitates inflammation and fibrosis of AT [43]. In animal models, LPS triggers gains in visceral AT and AT inflammation mediated via LPS's coreceptor, CD14 [44]. LPS also stimulates the proliferation of pre-adipocytes through a CD14 - dependent mechanism, possibly through activation of JAK/STAT and AMPK via cytosolic phospholipase A2 [45].

Moreover, obesity and HIV are both associated with a loss of gut microbial diversity and a deleterious metabolome [46]. The composition and biodiversity of the gut microbiota have been found to correlate with changes in weight in experimental animals and, to a lesser degree of evidence, also in humans [47, 48]. The microbiota, in turns, may influence levels of immunoactivation and translocation of microbial products, as well as being an active participant in the process of metabolization and digestion of certain nutrients [47].

WG is associated with increased transforming growth factor- $\beta$  that triggers a pro-fibrotic process to limit adipocyte hypertrophy. However, ectopic fat deposition occurs in sites such as the liver and skeletal muscle, worsening the proinflammatory state, metabolic dysregulation, and tissue hypoxia. Different studies documented a reduction of AT fibrosis and several inflammatory biomarkers during cART [43].

#### **Role of host-related factors**

Current literature regarding WG in PLWH also focuses on different host-related risk factors, such as age, sex, country of origin, and BMI at ART initiation. When considered, older age is often associated with a higher risk of WG [38, 49, 50]. However, a recent study showed that significant WG was not observed in geriatric PLWH who switched to a dolutegravir (DTG)-based regimen [51]. It cannot be excluded that the stability of weight over time in this study was rather the result of a relative increase in fat mass in a population with a high rate of lean mass loss, associated with age-related sarcopenia [52]. On the other hand, few studies have been conducted in children and adolescents, where WG during the growth stages is a desired factor and usually precedes height increase, while growth deficits often persist in young PLWH even after ART initiation, especially in low income countries [53]. However, in children and adolescents, no significant

differences in WG trajectories have been reported after switching from other regimens to INSTIs [54–56] although not all studies agree [57].

The country of origin of PLWH may also impact WG. For example, BMI was lower in patients living in low and low-middle income countries in Africa and Asia and higher in patients from middle-high- and high-income countries in a systematic review and meta-analysis of BMI changes among treatment-naïve patients who started ART [58]. Similarly, in the general people living without HIV, rates of overweight and obesity are considerably different depending on country and culture of origin, with north American men and South African women being the population with the highest prevalence of obesity, further increasing in recent years [59]. Many studies focusing on WG in course of ART pointed out how black people could be more prone to WG in certain settings, however behavioral and cultural differences are poorly investigated in most studies and might perhaps explain this data, also in light of the fact that WG is desired rather than unwelcomed by some patients for cultural reasons [60, 61]. Moreover, people from the same ethnicity may have different prevalence of overweight at baseline and during ART treatment depending on the country where they live, for instance in Latin Americans living in Latin America, the prevalence of obesity has been reported 5% before ART and 13% after three years of ART, while the corresponding frequencies for Latin Americans living in US or Canada were 15 and 22% [62], suggesting that lifestyle, more than ethnicity, may be relevant for WG. Therefore, socioeconomic status including marital status could strongly impact on WG in PLWH [41, 63], but it is an under reported neglected measure in HIV scientific literature. This may be a consequence of unmeasured various different cultural factors, or unobserved data on diet, physical activity and job, which have a significant impact on WG.

Sex also needs to be considered in evaluating host factors determining WG in PLWH on ART. Several studies highlighted an increased risk of WG in women compared with men [4, 34, 64, 65], but this is not confirmed worldwide, and there are conflicting results [38, 66]. Moreover, this is still largely unexplored in transgender PLWH.

The reason for the different incidence of WG in male and female are still under investigation. However, this difference reflects the epidemiology observed in the general population, where obesity is more prevalent in women than men in both developed and developing countries, and increase with age [67]. As estrogen promotes brown adipocyte differentiation while suppressing white adipose differentiation, some authors have hypothesized that, in the context of treated HIV infections, some ARVs might be correlated to higher effect on WG in women by interacting with this pathway. According to previous study,

INSTIs may interrupt adipose function via inhibition of estrogen action, as it was found that estrogen-mediated pathway was blocked by DTG by 70% and DTG administration to female mice inhibited oxygen consumption and energy expenditure by 15% without affecting food consumption [68]. Moreover, different inflammatory patterns and trajectories of inflammatory markers in course of ART have been observed in female compared to male PLWH, suggesting once again a possible interplay between inflammation and WG also in such context [42].

Finally, the role of body weight before ART initiation in determining WG is controversial in the literature. A lower baseline weight is generally considered to be a risk factor for WG [5, 37, 38, 49, 66, 69–72]. However, a cohort study of PLWH found no significant difference in WG when stratified by baseline weight [66]. In a French cohort of normal-weight patients at ART initiation, patients who retained a normal weight had a lower baseline BMI compared with those who became overweight or obese [41]. In addition, in switch studies, it appears that PLWH with higher BMI gain more weight, underscoring how, after the initial impact of ART on the virus and on an initial “return to health”, it may be lifestyles that impact more on the WG outcome [73, 74].

Another variable frequently associated with a higher risk of WG is smoking. In the Swiss HIV cohort study, smoking was significantly associated with general and abdominal obesity [36]. As smoking increases inflammation, it could also increase WG per se. However, smoking is not analyzed as a risk factor in most studies [63].

#### **Possible pathogenetic mechanisms related to antiretroviral drugs**

Many studies conducted in vitro in recent years have tried to find a biologically plausible explanation for the increased WG observed in course of some ARVs. One of the first hypothesis had been that INSTIs and, in particular, dolutegravir, could exert an inhibitory effect on  $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ -MSH), an anorexigenic neuropeptide, by binding of melanocortin 4 receptor, which may interfere with the regulation of food intake and lead to obesity [75]. However, this hypothesis was subsequently tested in vitro, founding that, for all INSTIs, drug concentrations substantially greater than clinical exposure are required for antagonism of the melanocortin-4 receptor to occur [76].

Another possible mechanism advocated to explain the weight gain is the interference of ARVs in the process of adipogenesis and energy expenditure of adipose tissue. In vitro data showed that drugs little associated to weight gain such as efavirenz and, to a lesser extent, elvitegravir, could alter adipocyte differentiation and induce pro-inflammatory cytokines, in a concentration-dependent manner, delaying acquisition of adipocyte morphology

and reducing the expression of adipogenesis marker genes such as PPAR $\gamma$ , glucose transporter GLUT4, lipoprotein lipase, and the adipokines adiponectin and leptin [77]. In contrast, raltegravir, and to a greater extent, dolutegravir, at peak concentration have been associated with elevated adipogenesis and lipid accumulation in adipocyte-differentiated adipose stem cells, suggesting these INSTIs may have a role in adipogenesis, lipogenesis, oxidative stress and insulin resistance [78]. In accordance with this hypothesis, raltegravir, dolutegravir, but also bictegravir and elvitegravir have been found to be able to increase adipogenesis in vitro, as demonstrated by the induction of higher levels of PPAR $\gamma$  and C/EBP $\alpha$  in adipocytes exposed to INSTIs compared to controls [79]. A recent study also found that PLWH on INSTIs, had reduced populations of metabolically activated CD9+ adipose tissue macrophages, that are considered metabolically beneficial, compared to that of uninfected controls ( $P < 0.001$ ). Moreover, BMCs of PLWH had lower fatty acid metabolism compared to those of uninfected controls ( $P < 0.01$ ) and, according to the analysis performed in murine macrophages, dolutegravir reduced lipid metabolism and increased expression of the fatty acid beta-oxidation enzyme Enoyl-CoA Hydratase, Short Chain 1 [80].

Dolutegravir has also been found to decrease oxygen consumption of preadipocytes, besides reducing, in course of adipocyte differentiation, triglyceride accumulation and adiponectin secretion, suggesting a possible additive mechanism of mitochondrial impairment [68, 81]. However, it is important to point out that all these data are derived only from in vitro studies, and there are currently no in vivo studies that correlate a molecular/cellular mechanism to the WG phenomenon, in addition to not always being confirmed the same results in different laboratory studies. Research in this field still requires an in-depth clinical field effort with longitudinal studies proving the presence or absence of the supposed mechanisms in people who gain or do not gain weight.

#### **RQ3. What is the available evidence on the clinical impact of ART on WG?**

WG in PLWH appears to be less evident in people treated with older NRTI and NNRTIs [70, 82–85] to the extent that a protective effect has been hypothesized, although not demonstrated, for some drugs of these classes, such as EFV and TDF [86–88]. However, high exposure to these drugs may be related to less WG because of gastrointestinal symptoms inducing anorexia, lipatrophy, or other unclear mechanisms. Indeed, in people who are extensive EFV metabolizers because of CYP2B6 polymorphisms, WG is similar to that observed with DTG [87]. Additionally, it is important to point out that, although EFV and TDF are less related to the

WG phenomenon compared with the newer ARVs, on the contrary, in older studies, TDF was associated with greater WG when compared with older ARVs, such as zidovudine or other nucleoside/nucleotide reverse transcriptase inhibitors, while EFV compared with nevirapine and even with protease inhibitors [70, 89]. This could suggest how, as the tolerability of ART improves, we see greater WG, not necessarily given by a side effect, but possibly related to an absence of toxicity. Regardless of the underlying mechanism, when a patient switches from an older drug to a newer ARV, WG is often significant [90]. For instance, PIs have been associated with higher WG compared with NNRTIs [69, 91–93], but the drugs with the highest impact on WG seem to be the newer ARVs, namely INSTIs and TAF [70, 72, 73, 94–96], which have an even more pronounced effect when they are used in combination [20, 97, 98]. However, it remains challenging to establish the role of a single agent in determining WG when, by definition, ART involves the use of at least two drugs and WG is known to have a multifactorial genesis. Also, it remains to be ascertained the role of a possible switch strategy to NNRTI or older treatments to contrast the phenomenon of WG. A proposal of switching from DTG to EFV and from TAF to TDF the study participants of the ADVANCE trial who had experienced the highest amount of WG, has been recently made by the authors of the study [99]. However, the patients themselves refused this proposal, besides being a step backward toward less innovative and less tolerated therapies [99, 100]. While the removal of TAF by switching from a TAF containing triple therapy to DTG and lamivudine two-drug therapy did not impact on weight gain [101], a first study comparing weight trajectories in people continuing TAF versus switching to TDF has been recently published in a North-European retrospective cohort of 292 patients [102]. In this study, people who remained on TAF increased their weight of mean +0.9 kg after one year, while those switched to TDF did not experience a significant weight increase during the same follow up. However the interpretation of these results is limited by the small number of participants (weight analysis at one year made on 90 PLWH on TAF and 65 PLWH on TDF) and by the retrospective design, while clinical trials evaluating the effect on weight of a switch strategy from INSTI to TAF/emtricitabine/darunavir/cobicistat (DEFINE trial, NCT04442737) or to Doravirine/Lamivudine/TDF (DeLiTE trial, NCT04665375), and from regimens containing both INSTIs and TAF to TDF/XTC/doravirine (NCT04636437), are in course and actively enrolling, to respond to the important question of which strategy could be better to face the problem.

In addition, given the lack of patients' perspective currently reported in the published literature concerning the switch of ARVs due to WG, a proper attention to

this topic should be paid in future studies. Indeed, a better evaluation of patients point of views may be of help to deepen the reason for switching or non-switching, to support the clinical decision.

#### ***Does TAF really contribute to body WG?***

Randomized controlled trials, including INSTI-based regimens in naïve PLWH, demonstrated a greater WG in patients starting TAF versus TDF that varied significantly (from a maximum of 6 kg in 48 weeks to a minimum of 3.6 kg in 96 weeks) largely depending on sex and race differences in the trial populations [20, 50, 70, 103, 104]. In addition, the AMBER study identified a greater WG in naïve PLWH taking TAF than those taking TDF (2 kg versus 1 kg in 96 weeks), both in combination with darunavir/cobicistat [105]. Data from observational studies also confirmed a possible contributing role of TAF in WG. In a recent analysis of the RESPOND cohort, including 14,703 ART naïve and ART-experienced PLWH, use of TAF (compared with lamivudine) was independently associated with a >7% increase in BMI [72]. These observations also apply to studies that only consider PLWH with HIV RNA <50 copies/mL, where a greater WG is generally observed after switching to TAF compared to TDF, but not to abacavir [7, 73, 104]. One of the hypotheses is that the WG reported in switch studies may be due, at least in part, to the loss of the protective effects of TDF and/or EFV rather than the effects of TAF [104]. This was also observed in the switch study to BIC/TAF/FTC [106]. In this study, weight change differed by previous NRTIs (+2.2 kg [F/TDF] and +0.6 kg [F/TAF],  $p < 0.001$ ), while no differences were found between BIC/TAF/FTC and DTG+TAF/FTC. Finally, in a pre-exposure prophylaxis (PrEP) study in people living without HIV taking TAF or TDF along with FTC, there was a difference of +1 kg in the TAF/FTC arm [107]. Therefore, whether TAF promotes WG or TDF reduces weight remains to be ascertained.

#### ***What is the role of INSTIs?***

In recent studies, INSTIs have been associated with an excess WG compared with other ARV classes [90]. However, differences exist among individual INSTIs and different study populations, with higher WG observed with DTG or BIC in naïve PLWH initiating first-line ART [20, 70, 91] than in switch studies, where results are somewhat conflicting [37, 56, 106, 108–111]. Moreover, WG was higher in studies performed in African and North American populations [20, 91, 112], and smaller in European cohorts [37, 51, 56, 108, 110].

The data on individual INSTIs are also controversial. Initially, DTG and BIC seemed to have the highest impact on WG, but further studies have also suggested a relevant role of RAL and EVG. DTG was the first drug

to be associated with WG [4, 91, 113]. In a retrospective observational cohort study [114] in 1152 ART-naïve PLWH, adjusted mean WG after 18 months was significantly higher with DTG (6.0 kg, 95% CI, 4.2–7.8) compared with NNRTIs (2.6 kg, 95% CI, 1.5–3.6) or EVG (0.5 kg, 95% CI, -1.0–2.0), while no significant difference was found compared with RAL (3.4 kg, 95% CI, 1.8–5.0) or PIs (4.1 kg, 95% CI, 3.2–5.0) [114]. Similar results were then confirmed in the larger observational NA-ACCORD study [91], where PLWH starting INSTI-based regimens had a mean estimated 5-year WG of +5.9 kg, compared with +3.7 kg with NNRTIs and +5.5 kg with PIs. Among PLWH starting INSTIs, the mean estimated 2-year WG was +7.2 kg for DTG, +5.8 kg for RAL, and +4.1 kg for EVG [91].

PLWH starting DTG in clinical trials experienced WG ranging between +2.1 and +7.1 kg after 96–144 weeks if ART-naïve [20, 70, 112, 115, 116], and between +0.8 and +0.98 kg after 48–96 weeks, if ART-experienced [117, 118]. This corresponds to a modest change in BMI over time, particularly in DTG switching strategies, with an unknown impact on long-term mortality or metabolic outcomes, especially in normal-weight people.

In studies in naïve PLWH, such as the STARTMRK, RAL was associated with similar increases in BMI compared with EFV after 156 weeks [119]. In addition, BMI increased by 3.8–4.7% in ART-naïve PLWH, similarly in the three study arms (DRV/r or ATV/r or RAL), in the AIDS Clinical Trials Group (ACTG) A5260s metabolic substudy of the A5257 randomized trial [22]. However, an analysis of the whole cohort of the A5257 study, showed that the initiation of RAL was associated with higher weight/BMI increases than ATV/r or DRV/r in treatment-naïve patients with normal BMI or who were underweight but became overweight or obese during follow-up [120]. Moreover, in the large, prospective, multicohort RESPOND collaboration, which included data on both ART-naïve and experienced PLWH, both RAL and DTG were found to be associated with an increased risk of both >7% and >30% BMI, while no increased risk was found for EVG [72]. In a pooled analysis of ACTG A5142, A5202, and A5257 (only the latter study included a group of patients on INSTI), a significantly greater WG was observed in women than in men [64]. In the WIHS cohort, PLWH on INSTI and/or TAF with a normal BMI at baseline had a significant risk of WG [121].

In a non-inferiority study of DTG/ABC/3TC versus BIC/FTC/TAF in ART-naïve PLWH, the median WG after 96 weeks was 2.4 and 3.6 kg, respectively [122]. In another non-inferiority study of DTG+FTC/TAF versus BIC/FTC/TAF in ART-naïve persons, the median changes in body weight after 96 weeks were +3.9 kg and +3.5 kg, respectively [123].

Cabotegravir (CAB) is the first long-acting injectable INSTI, recently approved for use in therapy and PrEP for HIV infection. A recent study investigating WG among 177 people living without HIV who received at least one injection of CAB or placebo (134 CAB; 43 placebo) found no difference between the two study arms [124]. On the other hand, when CAB was used in switching strategies in PLWH, a similar WG was observed between CAB and comparator ARTs [125].

#### **RQ4. What is the available evidence on the correlation of WG with clinical outcomes?**

##### ***Cardiovascular complications***

PLWH have an increased risk of CVD compared with people without HIV, regardless of the ART regimen [126]. However, the association between CV risk and ART-associated WG is controversial. For example, observational data showed that, although increases in BMI among ART-exposed PLWH were linked to an increased risk of T2DM, such changes did not show an association with increased CV risk [127]. In this study, CVD was defined as the first event from a composite of myocardial infarction (MI), sudden cardiac death, invasive CV procedure (coronary artery bypass graft or carotid endarterectomy), or stroke [127]. In addition, an increased long-term risk for major CV events was identified in PLWH who experienced a short-term gain in BMI (within 1 year from ART initiation), especially those with a baseline BMI within 18.5 and 25 kg/m<sup>2</sup> [5]. Of note, this is the only study to investigate the relationship between WG in ART-exposed individuals and CV risk.

##### ***Diabetes***

The risk of developing T2DM is associated with BMI in the general population [128]. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study on 43,278 person-years (N=9193) reported 125 diabetes events with an incidence rate ratio (IRR)/unit gain in BMI of 1.11 (95% confidence interval 1.03 to 1.21) regardless of the pre-ART BMI [5]. This suggests that the short-term gain in BMI following ART initiation appears to increase the risk of T2DM independently from baseline BMI [5]. A meta-analysis of 41 observational studies evaluating PLWH who were either ART-naïve or on ART found increased fasting blood glucose levels and an increased risk of developing T2DM in those treated with ART [129]. In the REPRIEVE study including 1848 PLWH on an INSTI-based regimen, INSTI use was not associated with a difference in mean fasting glucose, even when PLWH were stratified by natal sex [130]. Another meta-analysis across 44 studies also found ART to be a risk factor for T2DM development in some, but not all, studies [131]. A study comparing Taiwanese PLWH on ART (most commonly ≥2 NRTIs with NNRTIs or boosted or



unboosted PIs) with those not on ART showed that the risk of developing T2DM was associated with ART use [132]. The interplay between WG and ART regimens in the development of T2DM is a complex topic. Evidence is emerging on the association among WG, INSTIs, and T2DM. In PLWH switching to INSTIs, an increase in HbA1c was observed [86, 133]. In another cohort study, participants initiating INSTIs (particularly raltegravir) were more likely to develop T2DM than patients starting NNRTIs [93]. In the EMERALD trial, TAF was significantly associated with treatment-emergent T2DM compared with TDF [134]. In a retrospective analysis of the ADVANCE study data, among PLWH on INSTIs, obesity drove an increased risk of T2DM, especially in those taking TAF/FTC+DTG, with some evidence of greater CVD risk [97].

#### **Metabolic syndrome**

The prevalence of metabolic syndrome (MetS), characterized by central obesity and insulin resistance, is rapidly increasing in PLWH treated with cART [135]. Studies demonstrated that the incidence of MetS increases among PLWH, and its prevalence remains high after initiating ART [136, 137]. In the ADVANCE study, treatment-emergent MetS was observed, especially in the TAF/FTC+DTG arm and among women [20, 114]. However, ART is probably not the sole reason for these metabolic disorders since HIV is also likely to affect metabolism. The persistence of HIV in tissue reservoirs could synergize with some ART-enhancing metabolic disorders [138]. Mitochondrial dysfunction seems to be the most common underlying mechanism used by HIV and most ARVs to cause inflammation, insulin resistance, dyslipidemia, and lipodystrophy [139]. Findings indicate that PIs are more commonly implicated in MetS-related effects than other classes of ARVs, due to their ability to initiate many toxicities leading to MetS [138, 139]. Female gender, high BMI, and older age are major risk factors for the occurrence of MetS, and hypertriglyceridemia and low levels of high-density lipoproteins are the most common types of dyslipidemia [138].

#### **Chronic kidney disease**

PLWH have higher rates of chronic kidney disease (CKD), and studies have demonstrated an increased risk of CKD correlated with the use of ART [140–142]. Concerning the impact of WG on kidney function, large cohorts from Spain and the US found that PLWH with both end-stage renal disease (ESRD) and mild reduction of glomerular filtration rate (60–89 mL/min/1.73 m<sup>2</sup>) were more likely to have higher BMI at univariate analysis. However, when compared with PLWH with normal renal function, PLWH with reduced glomerular filtration rates had higher BMI, among other factors such as older

age, female gender, and NRTI or PI ritonavir-regimens [140, 143]. Despite the relevance of the research question, to our knowledge, so far no study directly assessed the issue on how increased WG impacts renal function among PLWH.

#### **Liver disease**

Non-AIDS-defining comorbidities in an aging population such as PLWH include non-alcoholic fatty liver disease (NAFLD), whose prevalence in the general population is estimated to be around 25%, and NAFLD is related to increasing weight as well as the development of MetS. In PLWH, the prevalence of NAFLD ranges between 13% and 73% [144, 145]. Specific HIV-related risk factors (e.g., persistent immune activation and ARV) may alter the course of liver disease [146]. Consistently with the return-to-health phenomenon, WG shortly after ART initiation was associated with improved survival in PLWH, particularly those with more advanced disease [90]. INSTIs and TAF are also associated with an increased risk of developing hepatic steatosis [147].

#### **Discussion**

This scoping review attempted to address four questions regarding WG in PLWH. For each, our literature interpretation only partially answered the question but helped us to define the following research agenda with improved clarity.

#### **Definition of WG in PLWH**

We believe that the complexity of the correlations between fat quantity and distribution and fat and lean mass and their implications at the clinical level cannot be resolved by simply evaluating the change in weight or BMI. We, therefore, suggest that the following non-exhaustive research program on how to appropriately define and measure WG in PLWH is addressed in future research: (I) develop a clinically meaningful data-driven definition of WG; (II) define methods of non-invasive assessment of weight and body composition to be used in clinical practice; (III) recognize the density of fat and lean tissue as a measure of their quality and function; (IV) study the interrelationship between fat and lean tissue and bone in metabolic homeostasis.

#### **Pathogenesis of WG in PLWH**

Further research is needed to understand how HIV infection and ART influence the complex interaction between AT, innate and cellular immune function, and metabolism. For host-related factors, meta-analyses may help resolve the observed conflicting results. Moreover, in future research, all relevant host-related factors must be recorded and considered while adjusting analyses for potential confounders (including smoking and

socioeconomic status, which are often unreported), to better identify, and to carefully manage with new intervention strategy PLWH at higher risk of WG.

### The impact of ART on WG

Further research is needed to establish how TAF and INSTI contribute to WG in PLWH, possibly highlighting the specific role of TAF by stopping TDF and/or EFV. Moreover, the impact of non-pharmaceutical intervention protocols against WG, like diet and physical exercise, should be considered.

### WG impact on clinical outcomes

Further studies are required to investigate: (I) the independent role of WG on clinical events compared with other metabolic factors and ART; (II) the role of specific HIV-related factors versus generic factors in the development of WG-related clinical events; (III) the association between ART and WG as a driver of clinical events.

### Limitations

This work presents the intrinsic limitations of the scoping reviews due to the related methodology. The evaluation of risk of bias of included studies is not performed. In addition, despite some indications on WG in children and adolescents are reported in the text, the authors are aware that the inclusion criteria referred only to adults WG. The comment on WG in children and adolescent has to be interpreted as a pure consideration of the state of the art.

Despite not directly adding scientific knowledge to the field, this work highlights the current knowledge gaps in the topic thus providing a future research agenda to fill the unmet requirements.

### Conclusion

This review illustrates knowledge gaps regarding WG in PLWH for each RQ, despite the rapidly growing number of articles on this topic. The literature is mainly focused on the role of drugs. However, the absence of a shared clinically meaningful definition of WG impairs comparability among studies and the opportunity to derive strong clinical guidance. Therefore, we believe our research agenda may help define future research and fill the knowledge gaps that have emerged from this review.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12879-023-08174-3>.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

### Acknowledgements

The authors thank Matteo Mucchetti of Health Publishing & Services Srl for methodological support and Renata Perego who provided medical writing assistance on behalf of Health Publishing & Services Srl.

### Authors' contributions

GG, PB, ADB, AG and AC conceived and designed the study. All authors evaluated literature, wrote, reviewed and approved the final manuscript.

### Funding

The realization of this article was made possible thanks to an unconditional contribution from Janssen Italy.

### Data availability

All data generated or analysed during this study are included in this published article and its supplementary information files.

### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

GG has received research grant and speaker honorarium from Gilead, Viiv, MERCK, and Janssen. He attended advisory boards of Gilead, Viiv, and MERCK. LT served as a consultant or attended advisory boards for Janssen, Gilead Sciences, Viiv Healthcare and received research grant by Gilead Sciences. The other authors have nothing to disclose.

Received: 29 September 2022 / Accepted: 17 March 2023

Published online: 14 April 2023

### References

1. Mankal PK, Kotler DP. From wasting to obesity, changes in nutritional concerns in HIV/AIDS. *Endocrinol Metab Clin North Am*. 2014;43(3):647–63. <https://doi.org/10.1016/j.ecl.2014.05.004>.
2. Freitas P, Carvalho D, Santos AC, Matos MJ, Madureira AJ, Marques R, et al. Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy. *J Endocrinol Invest*. 2012;35(11):964–70. <https://doi.org/10.3275/8187>.
3. Nduka CU, Uthman OA, Kimani PK, Stranges S. Body Fat Changes in People living with HIV on antiretroviral therapy. *AIDS Rev*. 2016;18(4):198–211.
4. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masanya M, et al. Dolutegravir plus two different Prodrugs of Tenofovir to treat HIV. *N Engl J Med*. 2019;381(9):803–15. <https://doi.org/10.1056/NEJMoa1902824>.
5. Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. *HIV Med*. 2016;17(4):255–68. <https://doi.org/10.1111/hiv.12294>.
6. Palella F, Hou Q, Li JM, Carlson JK, Durham M, Ward D et al. Weight gain among PWH who switch to ART-containing INSTIs or TAF. [CROI Abstract 504]. Abstracts from the virtual CROI 2021 Conference on Retroviruses and Opportunistic Infections. vCROI 2021 Abstract eBook, 2021: p. 189.
7. Surial B, Mugglin C, Calmy A, Cavassini M, Günthard HF, Stöckle M, et al. Weight and metabolic changes after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People living with HIV: a Cohort Study. *Ann Intern Med*. 2021;174(6):758–67. <https://doi.org/10.7326/m20-4853>.
8. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. 2005;8(1):19–32. <https://doi.org/10.1080/1364557032000119616>.
9. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci*. 2010;5:69. <https://doi.org/10.1186/1748-5908-5-69>.
10. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467–73. <https://doi.org/10.7326/M18-0850>.

11. Ryan DH, Yockey SR. Weight loss and improvement in Comorbidity: differences at 5%, 10%, 15%, and over. *Curr Obes Rep*. 2017;6(2):187–94. <https://doi.org/10.1007/s13679-017-0262-y>.
12. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI. Association between second-generation antipsychotics and changes in body mass index in adolescents. *J Adolesc Health*. 2013;52(3):336–43. <https://doi.org/10.1016/j.jadohealth.2012.10.272>.
13. Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F, et al. Relationship between weight gain and insulin resistance in people living with HIV switching to INSTI-based regimens. *AIDS*. 2022. <https://doi.org/10.1097/QAD.0000000000003289>.
14. Jih J, Mukherjee A, Vittinghoff E, Nguyen TT, Tsoh JY, Fukuoka Y, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. *Prev Med*. 2014;65:1–6. <https://doi.org/10.1016/j.ypmed.2014.04.010>.
15. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. *Physiol Rev*. 2013;93(1):359–404. <https://doi.org/10.1152/physrev.00033.2011>.
16. Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, Despres JP, Matsuura Y, Loos RJF, et al. *Obes Nat Rev Dis Primers*. 2017;3:17034. <https://doi.org/10.1038/nrdp.2017.34>.
17. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). *Ann Med*. 2012;44(1):82–92. <https://doi.org/10.3109/07853890.2010.526138>.
18. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation*. 2012;126(10):1301–13. <https://doi.org/10.1161/CIRCULATIONAHA.111.067264>.
19. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. *AIDS*. 2011;25(11):1405–14. <https://doi.org/10.1097/QAD.0b013e32834884e6>.
20. Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV*. 2020;7(10):e666–e76. [https://doi.org/10.1016/s2352-3018\(20\)30241-1](https://doi.org/10.1016/s2352-3018(20)30241-1).
21. Venter WDF, Hill A. Weighing considerations with newer antiretrovirals. *Lancet HIV*. 2020;7(6):e374–e5. [https://doi.org/10.1016/S2352-3018\(20\)30115-6](https://doi.org/10.1016/S2352-3018(20)30115-6).
22. Koethe JR, Moser C, Brown TT, Stein JH, Kelesidis T, Dube M, et al. Adipokines, Weight Gain and metabolic and inflammatory markers after antiretroviral therapy initiation: AIDS clinical trials Group (ACTG) A5260s. *Clin Infect Dis*. 2022;74(5):857–64. <https://doi.org/10.1093/cid/ciab542>.
23. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. *JACC Cardiovasc Imaging*. 2014;7(12):1221–35. <https://doi.org/10.1016/j.jcmg.2014.07.017>.
24. Murphy RA, Register TC, Shively CA, Carr JJ, Ge Y, Heilbrun ME, et al. Adipose tissue density, a novel biomarker predicting mortality risk in older adults. *J Gerontol A Biol Sci Med Sci*. 2014;69(1):109–17. <https://doi.org/10.1093/gerona/glt070>.
25. Alvey NJ, Pedley A, Rosenquist KJ, Massaro JM, O'Donnell CJ, Hoffmann U, et al. Association of fat density with subclinical atherosclerosis. *J Am Heart Assoc*. 2014;3(4). <https://doi.org/10.1161/JAHA.114.000788>.
26. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. *Diabetes*. 2010;59(11):2817–25. <https://doi.org/10.2337/db10-0585>.
27. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. *Int J Obes (Lond)*. 2008;32(Suppl 7):S2–4. <https://doi.org/10.1038/ijo.2008.238>.
28. Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, et al. Adipose tissue collagen VI in obesity. *J Clin Endocrinol Metab*. 2009;94(12):5155–62. <https://doi.org/10.1210/jc.2009>.
29. Yeoh AJ, Pedley A, Rosenquist KJ, Hoffmann U, Fox CS. The Association between Subcutaneous Fat Density and the propensity to Store Fat viscerally. *J Clin Endocrinol Metab*. 2015;100(8):E1056–64. <https://doi.org/10.1210/jc.2014.4032>.
30. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest*. 2003;112(12):1796–808. <https://doi.org/10.1172/JCI19246>.
31. Rosenquist KJ, Pedley A, Massaro JM, Theriksen KE, Murabito JM, Hoffmann U, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. *JACC Cardiovasc Imaging*. 2013;6(7):762–71. <https://doi.org/10.1016/j.jcmg.2012.11.021>.
32. Guaraldi G, Draisci S, Milic J, et al. Fat distribution and density in people living with HIV with  $\geq 5\%$  weight gain HIV. *J Int AIDS Soc*. 2020;23(Suppl 7):e25616; Abstract 0111.
33. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, et al. Energy expenditure and wasting in human immunodeficiency virus infection. *N Engl J Med*. 1995;333(2):83–8. <https://doi.org/10.1056/NEJM199507133330202>.
34. Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? *Antivir Ther*. 2012;17(7):1281–9. <https://doi.org/10.3851/imp2348>.
35. Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and weight gain in persons with HIV. *Curr HIV/AIDS Rep*. 2020;17(2):138–50. <https://doi.org/10.1007/s11904-020-00483-5>.
36. Barceló C, Guidi M, Thorball CW, Hammer C, Chaouch A, Scherrer AU, et al. Impact of genetic and nongenetic factors on body Mass Index and Waist-Hip ratio change in HIV-Infected individuals initiating antiretroviral therapy. *Open Forum Infect Dis*. 2020;7(1):ofz464. <https://doi.org/10.1093/ofid/ofz464>.
37. Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, et al. Weight gain: a possible side effect of all antiretrovirals. *Open Forum Infect Dis*. 2017;4(4):ofx239. <https://doi.org/10.1093/ofid/ofx239>.
38. Taramasso L, Bonfanti P, Ricci E, Orofino G, Squillace N, Menzaghi B, et al. Factors Associated with Weight Gain in People treated with Dolutegravir. *Open Forum Infect Dis*. 2020;7(6):ofaa195. <https://doi.org/10.1093/ofid/ofaa195>.
39. Wu KS, Anderson C, Little SJ. Integrase strand transfer inhibitors play the Main Role in Greater Weight Gain among Men with Acute and early HIV infection. *Open Forum Infect Dis*. 2021;8(1):ofaa619. <https://doi.org/10.1093/ofid/ofaa619>.
40. Shikuma CM, Gangcuangco LM, Killebrew DA, Libutti DE, Chow DC, Nakamoto BK, et al. The role of HIV and monocytes/macrophages in adipose tissue biology. *J Acquir Immune Defic Syndr*. 2014;65(2):151–9. <https://doi.org/10.1097/01.qai.0000435599.27727.6c>.
41. Goupil de Bouillé J, Vigouroux C, Plessis L, Ghislain M, Teglas JP, Boufassa F, et al. Factors Associated with being overweight and obesity in people living with human immunodeficiency virus on antiretroviral therapy: Socioclinical, inflammation, and metabolic markers. *J Infect Dis*. 2021;224(9):1570–80. <https://doi.org/10.1093/infdis/jiab151>.
42. Bares SH, Smeaton LM, Scott SE, Smith BA, Godfrey C, McCormsey GA. The Association between Weight Gain, Sex and Immune Activation following the initiation of antiretroviral therapy. *J Infect Dis*. 2021. <https://doi.org/10.1093/infdis/jiab210>.
43. Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, et al. Telmisartan Therapy does not improve lymph node or adipose tissue fibrosis more than continued antiretroviral therapy alone. *J Infect Dis*. 2018;217(11):1770–81. <https://doi.org/10.1093/infdis/jiy064>.
44. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*. 2007;56(7):1761–72. <https://doi.org/10.2337/db06-1491>.
45. Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. *Nat Rev Dis Primers*. 2020;6(1):48. <https://doi.org/10.1038/s41572-020-0181-1>.
46. Godfrey C, Bremer A, Alba D, Apovian C, Koethe JR, Koliwad S, et al. Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected individuals: immunopathogenic mechanisms and clinical implications. *J Infect Dis*. 2019;220(3):420–31. <https://doi.org/10.1093/infdis/jiz118>.
47. Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. *Gastroenterology*. 2017;152(7):1671–8. <https://doi.org/10.1053/j.gastro.2016.12.048>.
48. Holscher HD, Bauer LL, Gourineni V, Pelkman CL, Fahey GC Jr, Swanson KS. Agave Inulin supplementation affects the fecal microbiota of healthy adults participating in a Randomized, Double-Blind, Placebo-Controlled, crossover trial. *J Nutr*. 2015;145(9):2025–32. <https://doi.org/10.3945/jn.115.217331>.
49. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral

- therapy in the United States and Canada. *AIDS Res Hum Retroviruses*. 2016;32(1):50–8. <https://doi.org/10.1089/aid.2015.0147>.
50. Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for Weight Gain following switch to integrase inhibitor-based antiretroviral therapy. *Clin Infect Dis*. 2020;71(9):e471–e7. <https://doi.org/10.1093/cid/ciaa177>.
51. Guaraldi G, Calza S, Milic J, Calcagno A, Focà E, Rota M, et al. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. *Aids*. 2021;35(6):939–45. <https://doi.org/10.1097/qad.0000000000002853>.
52. Bourgi K, Wanjalla C, Koethe JR. Inflammation and metabolic complications in HIV. *Curr HIV/AIDS Rep*. 2018;15(5):371–81. <https://doi.org/10.1007/s11904-018-0411-2>.
53. McGrath CJ, Diener L, Richardson BA, Peacock-Chambers E, John-Stewart GC. Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis. *AIDS*. 2015;29(15):2009–23. <https://doi.org/10.1097/QAD.0000000000000783>.
54. Frange P, Avettand-Fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a french paediatric cohort. *HIV Med*. 2022. <https://doi.org/10.1111/hiv.13302>.
55. Yeoh DK, Campbell AJ, Bowen AC. Increase in body Mass Index in Children with HIV, switched to Tenofovir Alafenamide Fumarate or Dolutegravir containing antiretroviral regimens. *Pediatr Infect Dis J*. 2021;40(5):e215–e6. <https://doi.org/10.1097/inf.0000000000003076>.
56. Taramasso L, Di Biagio A, Bovis F, Forlanini F, Albani E, Papaioannu R, et al. Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-Infected young adults and adolescents: a 10-Year observational study. *Microorganisms*. 2020;8(6). <https://doi.org/10.3390/microorganisms8060864>.
57. Koay WLA, Dirajlal-Fargo S, Levy ME, Kulie P, Monroe A, Castel AD, et al. Integrase strand transfer inhibitors and Weight Gain in Children and Youth with Perinatal Human Immunodeficiency Virus in the DC Cohort. *Open Forum Infect Dis*. 2021;8(7):ofab308. <https://doi.org/10.1093/ofid/ofab308>.
58. Olawepo JO, Pharr JR, Cross CL, Kachen A, Olakunde BO, Sy FS. Changes in body mass index among people living with HIV who are new on highly active antiretroviral therapy: a systematic review and meta-analysis. *AIDS Care*. 2021;33(3):326–36. <https://doi.org/10.1080/09540121.2020.1770181>.
59. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet*. 2011;377(9765):557–67. [https://doi.org/10.1016/S0140-6736\(10\)62037-5](https://doi.org/10.1016/S0140-6736(10)62037-5).
60. Alhassan Y, Twimukye A, Malaba T, Myer L, Waitt C, Lamorde M, et al. It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda. *BMC Womens Health*. 2022;22(1):246. <https://doi.org/10.1186/s12905-022-01814-x>.
61. Venter WDF, Moorhouse M, Sokhela S, Akpomiemie G, Qavi A, McCann K et al. Dolutegravir plus two different formulations of tenofovir, and emtricitabine, for the treatment of HIV-1 infection: ADVANCE trial; IAS 2019, slides MOAX0102LB available at: [https://programme.ias2019.org/PAGMaterial/PPT/1875\\_4149/Venter%20ADVANCE.pptx](https://programme.ias2019.org/PAGMaterial/PPT/1875_4149/Venter%20ADVANCE.pptx)
62. Coelho LE. Weight Gain Post-ART in HIV + Latinos/As Differs in the US, Canada, and Latin America (Abstract #510). CROI 2021.
63. Taylor BS, Liang Y, Garduño LS, Walter EA, Gerardi MB, Anstead GM, et al. High risk of obesity and weight gain for HIV-infected uninsured minorities. *J Acquir Immune Defic Syndr*. 2014;65(2):e33–40. <https://doi.org/10.1097/qai.000000000000010>.
64. Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-Infected Women Gain more weight than HIV-Infected Men following the initiation of antiretroviral therapy. *J Womens Health (Larchmt)*. 2018;27(9):1162–9. <https://doi.org/10.1089/jwh.2017.6717>.
65. Costa CRB, Melo ES, Antonini M, Jesus GJ, Pontes PS, Gir E, et al. Association between sociodemographic and behavioral factors with metabolic syndrome in people living with HIV. *Rev Gaucha Enferm*. 2019;40:e20180379. <https://doi.org/10.1590/1983-1447.2019.20180379>.
66. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. *AIDS Res Hum Retroviruses*. 2013;29(3):435–40. <https://doi.org/10.1089/aid.2012.0234>.
67. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of Disease Study 2013. *Lancet*. 2014;384(9945):766–81. [https://doi.org/10.1016/S0140-6736\(14\)60460-8](https://doi.org/10.1016/S0140-6736(14)60460-8).
68. Jung I, Jin S, Tu-Sekine B et al. Integrase Inhibitors Target Mitochondria in Brown Adipocytes Disrupting Thermogenesis [CROI Abstract 515]. Abstracts from the virtual CROI 2021 Conference on Retroviruses and Opportunistic Infections. vCROI 2021 Abstract eBook, 2021: p. 194.
69. Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. *Clin Infect Dis*. 2015;60(12):1852–9. <https://doi.org/10.1093/cid/civ192>.
70. Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight Gain following initiation of antiretroviral therapy: risk factors in Randomized comparative clinical trials. *Clin Infect Dis*. 2020;71(6):1379–89. <https://doi.org/10.1093/cid/ciz999>.
71. Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, et al. Inflammation and change in Body Weight with antiretroviral therapy initiation in a multinational cohort of HIV-Infected adults. *J Infect Dis*. 2016;214(1):65–72. <https://doi.org/10.1093/infdis/jiw096>.
72. Bansil-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. *Lancet HIV*. 2021;8(11):e711–e22. [https://doi.org/10.1016/s2352-3018\(21\)00163-6](https://doi.org/10.1016/s2352-3018(21)00163-6).
73. Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to dolutegravir alafenamide determines weight gain in patients on rilpivirine-based regimen. *Aids*. 2020;34(6):877–81. <https://doi.org/10.1097/qad.0000000000002496>.
74. Currier J. Themed discussion "Fat in focus". CROI 2020, Boston.
75. Committee for Medicinal Products for Human Use (CHMP). European medicines agency. Assessment report. Dolutegravir (Tivicay). November 21, 2013.
76. McMahon C, Trevaskis JL, Carter C, Holsapple K, White K, Das M, et al. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. *PLoS ONE*. 2020;15(2):e0229617. <https://doi.org/10.1371/journal.pone.0229617>.
77. Moure R, Domingo P, Gallego-Escuredo JM, Villarroya J, Gutierrez Mdel M, Mateo MG, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. *Antiviral Res*. 2016;132:59–65. <https://doi.org/10.1016/j.antiviral.2016.05.013>.
78. Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The integrase inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and induce insulin resistance in Human/Simian adipose tissue and human adipocytes. *Clin Infect Dis*. 2020;71(10):e549–e60. <https://doi.org/10.1093/cid/ciaa259>.
79. Carleo MA, Perna A, Rosario P et al. Adipocyte Differentiation and Antiretroviral Drugs: an In Vitro Model [CROI Abstract 599]. In Special Issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. *Top Antiv Med*. 2022;30(1s):234.
80. Vakili S, Paneru B, Guerrier CM, Miller J, Baumrin E, Forrester A, et al. Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing ART. *AIDS*. 2022. <https://doi.org/10.1097/QAD.00000000000003278>.
81. Pickering RT, Soden KM, Asundi A. N. L. Metabolic Perturbations by Integrase Inhibitors in Differentiated Human Adipocytes [CROI Abstract 600]. In Special Issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. *Top Antiv Med*. 2022;30(1s):234.
82. Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. *Clin Gastroenterol Hepatol*. 2010;8(2):183–91. <https://doi.org/10.1016/j.cgh.2009.09.025>.
83. Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. *J Antimicrob Chemother*. 2018;73(8):2177–85. <https://doi.org/10.1093/jac/dky145>.
84. Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, et al. Obesity Trends and Body Mass Index Changes after starting antiretroviral treatment: the swiss HIV Cohort Study. *Open Forum Infect Dis*. 2014;1(2):ofu040. <https://doi.org/10.1093/ofid/ofu040>.
85. Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. *J Acquir Immune Defic Syndr*. 2007;44(5):506–17. <https://doi.org/10.1097/QAI.0b013e31804216cf>.

86. Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from Efavirenz-Based to integrase strand transfer inhibitor-based regimens. *J Acquir Immune Defic Syndr*. 2017;76(5):527–31. <https://doi.org/10.1097/qai.0000000000001525>.
87. Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, et al. CYP2B6 genotype and weight gain differences between Dolutegravir and Efavirenz. *Clin Infect Dis*. 2021;73(11):e3902–e9. <https://doi.org/10.1093/cid/ciaa1073>.
88. Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. *Curr Opin Infect Dis*. 2021;34(1):16–24. <https://doi.org/10.1097/qco.0000000000000695>.
89. Huisin 't Veld D, Balestre E, Buyze J, Menten J, Jaquet A, Cooper DA, et al. Determinants of Weight Evolution among HIV-Positive patients initiating antiretroviral treatment in low-resource settings. *J Acquir Immune Defic Syndr*. 2015;70(2):146–54. <https://doi.org/10.1097/qai.0000000000000691>.
90. Shah S, Hindley L, Hill A. Are New Antiretroviral Treatments increasing the risk of Weight Gain? *Drugs*. 2021;81(3):299–315. <https://doi.org/10.1007/s40265-020-01457-y>.
91. Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. *J Int AIDS Soc*. 2020;23(4):e25484. <https://doi.org/10.1002/jia2.25484>.
92. Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, et al. Brief report: Weight Gain following ART initiation in ART-Naive people living with HIV in the current treatment era. *J Acquir Immune Defic Syndr*. 2021;86(3):339–43. <https://doi.org/10.1097/qai.0000000000002556>.
93. Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, et al. Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with integrase inhibitor-based initial antiretroviral therapy among persons with Human Immunodeficiency Virus in the United States and Canada. *Clin Infect Dis*. 2021;73(7):e2234–e42. <https://doi.org/10.1093/cid/ciaa1403>.
94. Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. *J Int AIDS Soc*. 2021;24(4):e25702. <https://doi.org/10.1002/jia2.25702>.
95. Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. *Curr Med Res Opin*. 2020;36(8):1313–23. <https://doi.org/10.1080/03007995.2020.1775074>.
96. Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, et al. Changes in Waist circumference in HIV-Infected individuals initiating a raltegravir or protease inhibitor regimen: Effects of Sex and Race. *Open Forum Infect Dis*. 2018;5(11):ofy201. <https://doi.org/10.1093/ofid/ofy201>.
97. McCann K, Shah S, Hindley L, Hill A, Qavi A, Simmons B, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. *Aids*. 2021;35(10):1657–65. <https://doi.org/10.1097/qad.0000000000002930>.
98. Kanda N, Okamoto K, Okumura H, Mieno M, Sakashita K, Sasahara T, et al. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. *HIV Med*. 2021;22(6):457–66. <https://doi.org/10.1111/hiv.13061>.
99. Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, et al. Weight gain stopping/switch rules for antiretroviral clinical trials. *Aids*. 2021;35(Suppl 2):183–s8. <https://doi.org/10.1097/qad.0000000000003092>.
100. Taramasso L, Di Biagio A, Guaraldi GAIDS. 2022, accepted article, in press.
101. van Wyk J, Ait-Khaled M, Santos J, Scholten S, Wohlfeiler M, Ajana F, et al. Improvement in Metabolic Health Parameters at Week 48 after switching from a Tenofovir Alafenamide-Based 3- or 4-Drug regimen to the 2-Drug regimen of Dolutegravir/Lamivudine: the TANGO study. *J Acquir Immune Defic Syndr*. 2021. <https://doi.org/10.1097/qai.0000000000002655>.
102. Kauppinen KJ, Aho I, Sutinen J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. *AIDS*. 2022;36(10):1337–44. <https://doi.org/10.1097/QAD.0000000000003245>.
103. Erlandson KM, Wu K, Lake JE, Samuels DC, Bares SH, Tassiopoulos K, et al. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. *Aids*. 2021;35(3):439–45. <https://doi.org/10.1097/qad.0000000000002771>.
104. Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: Pooled Data from Randomized clinical trials. *Clin Infect Dis*. 2021;73(8):1440–51. <https://doi.org/10.1093/cid/ciab444>.
105. Orkin C, Eron JJ, Rockstroh J, Podzamczar D, Esser S, Vandekerckhove L, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. *AIDS*. 2020;34(5):707–18. <https://doi.org/10.1097/QAD.0000000000002463>.
106. Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to Bicittegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically suppressed adults with Human Immunodeficiency Virus. *Clin Infect Dis*. 2021;73(2):e485–e93. <https://doi.org/10.1093/cid/ciaa988>.
107. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet*. 2020;396(10246):239–54. [https://doi.org/10.1016/S0140-6736\(20\)31065-5](https://doi.org/10.1016/S0140-6736(20)31065-5).
108. Burns JE, Stirrup OT, Dunn D, Runcie-Unger I, Milinkovic A, Candfield S, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. *Aids*. 2020;34(11):109–14. <https://doi.org/10.1097/qad.0000000000002379>.
109. Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, et al. Switching to Bicittegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans with HIV-1: a randomized phase 3b, Multicenter, open-label study. *J Acquir Immune Defic Syndr*. 2021;88(1):86–95. <https://doi.org/10.1097/QAI.0000000000002731>.
110. Verboeket SO, Boyd A, Wit FW, Verheij E, van der Schim MF, Kootstra N, et al. Bicittegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV aged >= 65 years: Week 48 results of a phase 3b, open-label trial. *Infect Dis Ther*. 2021;10(2):775–88. <https://doi.org/10.1007/s40121-021-00419-5>.
111. Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV*. 2020;7(10):e677–e87. [https://doi.org/10.1016/S2352-3018\(20\)30238-1](https://doi.org/10.1016/S2352-3018(20)30238-1).
112. Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? *AIDS*. 2017;31(10):1499–500. <https://doi.org/10.1097/QAD.0000000000001495>.
113. Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgian T, Raffanti SP, et al. Greater Weight Gain in treatment-naïve persons starting Dolutegravir-based antiretroviral therapy. *Clin Infect Dis*. 2020;70(7):1267–74. <https://doi.org/10.1093/cid/ciz407>.
114. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. Fixed-dose combination bicittegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. *Lancet HIV*. 2020;7(6):e389–e400. [https://doi.org/10.1016/S2352-3018\(20\)30099-0](https://doi.org/10.1016/S2352-3018(20)30099-0).
115. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Durable efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naïve adults with HIV-1 infection: 96-Week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr*. 2020;83(3):310–8. <https://doi.org/10.1097/QAI.0000000000002275>.
116. Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Immediate Versus Deferred switching from a boosted protease inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically suppressed patients with High Cardiovascular Risk or Age >=50 years: final 96-Week results of the NEAT022 study. *Clin Infect Dis*. 2019;68(4):597–606. <https://doi.org/10.1093/cid/ciy505>.
117. van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to Dolutegravir/Lamivudine fixed-dose 2-Drug regimen vs continuing a Tenofovir Alafenamide-Based 3- or 4-Drug regimen for maintenance of Virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, Randomized, Noninferiority TANGO Study. *Clin Infect Dis*. 2020;71(8):1920–9. <https://doi.org/10.1093/cid/ciz1243>.
118. Rockstroh JK, Lennox JL, DeJesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/

- emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. *Clin Infect Dis*. 2011;53(8):807–16. <https://doi.org/10.1093/cid/cir510>.
120. Ofofokun I, Na LH, Landovitz RJ, Ribaldo HJ, McComsey GA, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. *Clin Infect Dis*. 2015;60(12):1842–51. <https://doi.org/10.1093/cid/civ193>.
121. Lahiri CD, Xu Y, Wang K, Alvarez JA, Sheth AN, O'Halloran J, et al. Weight and body Mass Index Change after switching to integrase inhibitors or Tenofovir Alafenamide among Women living with HIV. *AIDS Res Hum Retroviruses*. 2021;37(6):461–7. <https://doi.org/10.1089/aid.2020.0197>.
122. Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019;6(6):e355–e63. [https://doi.org/10.1016/S2352-3018\(19\)30077-3](https://doi.org/10.1016/S2352-3018(19)30077-3).
123. Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019;6(6):e364–e72. [https://doi.org/10.1016/S2352-3018\(19\)30080-3](https://doi.org/10.1016/S2352-3018(19)30080-3).
124. Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, et al. Cabotegravir is not Associated with Weight Gain in Human Immunodeficiency Virus-uninfected individuals in HPTN 077. *Clin Infect Dis*. 2020;70(2):319–22. <https://doi.org/10.1093/cid/ciz439>.
125. Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. *N Engl J Med*. 2020;382(12):1124–35. <https://doi.org/10.1056/NEJMoa1909512>.
126. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, Prevention, and management of Cardiovascular Disease in People living with HIV: A Scientific Statement from the American Heart Association. *Circulation*. 2019;140(2):e98–e124. <https://doi.org/10.1161/CIR.0000000000000695>.
127. Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, et al. Effect of changes in body Mass Index on the risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive individuals: results from the D:A:D study. *J Acquir Immune Defic Syndr*. 2021;86(5):579–86. <https://doi.org/10.1097/qai.0000000000002603>.
128. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. *J Cardiovasc Nurs*. 2002;16(2):17–23. <https://doi.org/10.1097/00005082-200201000-00003>.
129. Nduka CU, Stranges S, Kimani PK, Sarki AM, Uthman OA. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. *Diabetes Metab Res Rev*. 2017;33(6). <https://doi.org/10.1002/dmrr.2902>.
130. Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary Cardiovascular Prevention Cohort of People with Human Immunodeficiency Virus. *Open Forum Infect Dis*. 2021;8(12):ofab537. <https://doi.org/10.1093/ofid/ofab537>.
131. Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ. Incidence and risk factors for Prediabetes and Diabetes Mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and Meta-analysis. *Epidemiology*. 2018;29(3):431–41. <https://doi.org/10.1097/EDE.0000000000000815>.
132. Lin SP, Wu CY, Wang CB, Li TC, Ko NY, Shi ZY. Risk of diabetes mellitus in HIV-infected patients receiving highly active antiretroviral therapy: a nationwide population-based study. *Med (Baltim)*. 2018;97(36):e12268. <https://doi.org/10.1097/MD.00000000000012268>.
133. Summers NA, Lahiri CD, Angert CD, Aldredge A, Mehta CC, Ofofokun I, et al. Metabolic changes Associated with the use of integrase strand transfer inhibitors among virally controlled women. *J Acquir Immune Defic Syndr*. 2020;85(3):355–62. <https://doi.org/10.1097/qai.0000000000002447>.
134. Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. *Antiviral Res*. 2019;170:104543. <https://doi.org/10.1016/j.antiviral.2019.104543>
135. Lagathu C, Bereziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. *Expert Opin Drug Saf*. 2019;18(9):829–40. <https://doi.org/10.1080/14740338.2019.1644317>.
136. Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, et al. Changes in metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naïve HIV-infected individuals. *J Acquir Immune Defic Syndr*. 2012;61(3):381–9. <https://doi.org/10.1097/QAI.0b013e3182690e3c>.
137. Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, et al. Changes in metabolic syndrome status after initiation of antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2015;68(1):73–80. <https://doi.org/10.1097/QAI.0000000000000397>.
138. Ergin HE, Inga EE, Maung TZ, Javed M, Khan S. HIV. Antiretroviral therapy and metabolic alterations: a review. *Cureus*. 2020;12(5):e8059. <https://doi.org/10.7759/cureus.8059>.
139. Mohan J, Ghazi T, Chuturgoon AA. A critical review of the biochemical mechanisms and epigenetic modifications in HIV- and Antiretroviral-Induced metabolic syndrome. *Int J Mol Sci*. 2021;22(21). <https://doi.org/10.3390/ijms222112020>.
140. Cristelli MP, Trullas JC, Cofan F, Rico N, Manzardo C, Ambrosioni J, et al. Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. *Braz J Infect Dis*. 2018;22(3):193–201. <https://doi.org/10.1016/j.bjid.2018.05.001>.
141. Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. *Kidney Int*. 2014;86(2):259–65. <https://doi.org/10.1038/ki.2014.44>.
142. Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. *Infect Dis Clin North Am*. 2014;28(3):457–76. <https://doi.org/10.1016/j.idc.2014.05.003>.
143. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. *Am J Kidney Dis*. 2012;59(5):628–35. <https://doi.org/10.1053/j.ajkd.2011.10.050>.
144. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis*. 2008;47(2):250–7. <https://doi.org/10.1086/589294>.
145. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. *Hepatology*. 2016;64(1):19–22. <https://doi.org/10.1002/hep.28524>.
146. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? *Curr Opin HIV AIDS*. 2014;9(4):365–70. <https://doi.org/10.1097/COH.0000000000000064>.
147. Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). *EClinicalMedicine*. 2021;40:101116. <https://doi.org/10.1016/j.eclinm.2021.101116>.

## Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.